This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In our study population of 1000 thrombectomy‐eligible patients (513 women; median age, 77 years [interquartile range, 67–84]), IVT emerged as a predictor of favorable functional outcome (modified Rankin Scale score, 0–2) independent of modified mTICI score (adjusted odds ratio, 0.49 [95% CI, 0.32–0.75];P=0.001). 0.75];P=0.001).
We performed sensitivity analysis using propensity score matching.Results:In our study population of 1000 thrombectomy-eligible patients (513 females, median age 77 [67-84, interquartile range]) IVT emerged as predictor of favorable functional outcome (mRS 0-2) independent of mTICI (adjusted OR 0.49; 95% CI [0.32;0.75]; p=0.001).
The role of adjunctive intravenous thrombolysis, such as intravenous tissue plasminogen activator (IVtPA), with MT remains unclear, especially for medium vessel occlusion (MeVO). In univariable regression, all outcomes were comparable between the two groups, except for higher mRS 0-2 rates in the MT+IVtPA group.
Background:Early prediction of functional outcome after rtPA helps clinicians in prognostic conversations with stroke patients and their families. modified Rankin Scale (mRS) at one month, classified into good (mRS 2) and poor (mRS 5) outcomes was noted. 0.90) and poor outcomes (AUC=0.84, 95%CI:0.76-0.91). 0.90) outcomes.
This study aims to elucidate the outcomes and factors contributing to achieving excellent recanalization (mTICI 2c-3) versus successful recanalization (mTICI 2b) in MeVO stroke patients undergoing mechanical thrombectomy (MT).Methods:We Further prospective studies and randomized controlled trials are warranted for validation.
However, clinical outcomes remain similar. This study compares post-thrombectomy outcomes in both groups, matched by initial NIHSS scores.Method:From October 2017 to March 2023, we studied LVO cases undergoing thrombectomy for acute ischemic stroke. Devastating outcomes were higher in ICAD group (15% vs 39%,P=0.027).
Pre-transfer variables independently associated with clinical improvement were intravenous thrombolysis use, more distal occlusions, and lower serum glucose; variables associated with deterioration included more proximal occlusions and higher serum glucose.
of these patients received IV thrombolysis and 32.4% received IV thrombolysis and 43.9% Further studies are needed to determine why young adults with LVO with LAA have worse outcomes. Introduction:The incidence of Large Vessel Occlusion-Acute Ischemic Stroke (LVO-AIS) continues to increase in young adults. went home, 12.9%
Introduction:Tenecteplase improves reperfusion and functional outcomes in stroke patients with large vessel occlusion. Primary outcome was mRS at 90 days. Secondary outcomes were NIHSS at 24 hours and at discharge. Secondary outcomes were NIHSS at 24 hours and at discharge. Median NIHSS at presentation (18.0 versus 16.0,
Regional collateral status on initial angiogram, expanded Thrombolysis in Cerebral Infarction (eTICI) grade on final angiogram, and regional unfavorable tissue outcome with the appearance of low or high density on CT 24 h after MT were recorded. Categorizing cortical areas resulted in 256 areas in group A and 171 in group B.
Background:Slow flow phenomenon is impaired coronary flow during percutaneous coronary intervention (PCI) in absence of mechanical obstruction, and it is associated with deteriorated outcome.
This study is aimedaims at to establishing MSU time metrics and implementing strategies to improve the efficiency of prehospital stroke care.Methods:We analyzed data from 289 patients admitted to the MSU between the years of 2017-2023.
Methods:From our prospectively collected multi-center registry across four comprehensive stroke centers (CSC) in the Greater Houston area, we identified patients from 2017 to 2023 with LVO AIS who received EVT. FIV was defined using MRI DWI at 48 hours. Large infarct core was defined by CTP as exceeding 70 ml or by CT ASPECTS < 6.
Discovering discrepancies in a major published trial from the pharma-academic complex would be a boost to those seeking to force trial data to be public, and that is exactly what a group of investigators attempted to do with a major cholesterol lowering trial published in 2017. But first, some background. Cholesterol lowering is big business.
Details cannot be shared here, but suffice it to say that inability to recognize acute occlusive myocardial infarction in the presence of ventricular paced rhythm contributed to a poor outcome. European Heart Journal 38(41):3082-3089; November 1, 2017. After showing an ECG with paced rhythm that clearly shows acute MI, K.
The Times also briefly touches on some other patients of Mustapha who had bad outcomes. Jeffery Dormu was a double board certified vascular surgeon who was paid $13 million dollars by Medicare alone between 2013 and 2017. A thrombolysis is performed in the hospital via a catheter. The procedures were unsuccessful, and Ms.
BACKGROUND:There is limited information on the delivery of acute stroke therapies and secondary preventive measures and clinical outcomes over time in young adults with acute ischemic stroke. The observation period was divided into 4 epochs: 2008 to 2010, 2011 to 2013, 2014 to 2016, and 2017 to 2019. men, 71.9%) were registered.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
45 
Let's personalize your content